FDA suspects meningitis risk with 2 more NECC drugs; Novartis clings to 69% share of Diovan HCT sales;

@FiercePharma: Other compounded drugs may be tied into meningitis outbreak, FDA says. Another NECC steroid + NECC heart drug. More | Follow @FiercePharma

> Two more drugs sold by New England Compounding are suspected in the growing meningitis outbreak, which has so far killed 15 patients and sickened more than 200. Report | Report

> Three weeks after its U.S. patent expiration, Novartis ($NVS) has kept 69% of the market for Diovan HCT, a combination version of its hypertension drug, in part because of its own authorized generic version. Report

> Sanofi ($SNY) is expanding its Turkish operations to make a production plant in Luleburgaz a hub for antibiotics export to 40 countries. Report

> Novo Nordisk ($NVO) filed for regulatory approval of its new hemophilia treatment turoctocog alfa in Europe and the U.S. Report | Release

> Ireland's Jazz Pharmaceuticals said it wrapped up the sale of its women's health business to Sweden's Meda. Report

Medical Device News

 @FierceMedDev: JNJ pulled in $7.1 billion from medical devices and diagnostics in Q3, a 12.5% jump. More | Follow @FierceMedDev

 @MarkHFierce: Patients in India thrived with used ICD implants. Can this be done on a broader scale? More | Follow @MarkHFierce

 @DamianFierce: Medtronic is buying a $66.2M stake in China's LifeTech Scientific, makers of cardiovascular devices. More | Follow @DamianFierce

> Amid Dx sales growth, Roche Diagnostics considers another buy. News

> Lanx draws $8.7M for spinal fusion device development. Item

Biotech News

 @FierceBiotech: New special report on FierceVaccines.com: 10 promising therapeutic vaccines in 2012. Feature | Follow @FierceBiotech

 @JohnCFierce: Genzyme, likely to get some tough safety questions on Kynamro at this week's FDA panel. More | Follow @JohnCFierce

 @RyanMFierce: Piramal is poised to be a big consolidator in pharma services/manufacturing, but apparently only at the right price. More | Follow @RyanMFierce

> FDA frets over safety of Genzyme's rival drug for rare cholesterol disease. Article

> Bullish Roche talks targeted takeovers, showcases T-DM1's prospects. Story

> ArQule, Threshold get a bounce out of PhIII SPA pacts with FDA. Report

Biotech Research News

> NIH funds Advanced Cancer Therapeutics' preclinical brain cancer drug work. Report

> Scientists flee $3B Texas cancer research fund. Item

> Alnylam, Tel Aviv U develop RNAi drugs to fight rare blood cancer. Article

> Alzheimer's drug builds new brain cell connections in rats. News

> Scientists build neural-like stem cells from mouse muscle tissue. Story

Pharma Manufacturing News

> GSK cancels plans to close Stiefel plant in Ireland. Story

> Cinven continues generics deal spree with Amdipharm buy. Article

> Teva Pharma opens $110M plant in Hungary. News

> Analysis: Compounding groups fought FDA oversight before NECC disaster. Report

And Finally... A CVS Caremark unit agreed to pay $5.25 million to settle claims that it misrepresented prices of certain Medicare prescription drugs, the Department of Justice said. Report

Suggested Articles

The FDA has slapped a U.S. drug repackager, saying in a warning letter that its storage processes and equipment cleaning are not up to expectations.

By extending the tender offer for just six days, Roche seems confident it will receive positive reviews from U.S. and U.K. watchdogs in time.

Back in June, Takeda scrapped a Ninlaro trial in rare disease light-chain (AL) amyloidosis. Saturday, it shared the data behind the decision.